26 reports of this reaction
2.7% of all NEOSTIGMINE METHYLSULFATE reports
#2 most reported adverse reaction
ABDOMINAL DISTENSION is the #2 most commonly reported adverse reaction for NEOSTIGMINE METHYLSULFATE, manufactured by Exela Pharma Sciences, LLC. There are 26 FDA adverse event reports linking NEOSTIGMINE METHYLSULFATE to ABDOMINAL DISTENSION. This represents approximately 2.7% of all 959 adverse event reports for this drug.
Patients taking NEOSTIGMINE METHYLSULFATE who experience abdominal distension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ABDOMINAL DISTENSION is a less commonly reported adverse event for NEOSTIGMINE METHYLSULFATE, but still significant enough to appear in the safety profile.
In addition to abdominal distension, the following adverse reactions have been reported for NEOSTIGMINE METHYLSULFATE:
The following drugs have also been linked to abdominal distension in FDA adverse event reports:
ABDOMINAL DISTENSION has been reported as an adverse event in 26 FDA reports for NEOSTIGMINE METHYLSULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ABDOMINAL DISTENSION accounts for approximately 2.7% of all adverse event reports for NEOSTIGMINE METHYLSULFATE, making it one of the most commonly reported side effect.
If you experience abdominal distension while taking NEOSTIGMINE METHYLSULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.